Abstract
The use of immune-checkpoint inhibitors targeting the CTLA-4, PD-1, or PD-L1 signalling axis in the modulation of anti-tumour T-cell activity has revolutionised the treatment of lung cancer in different settings.1 In patients with PD-L1 expression of at least 50%, pembrolizumab (anti PD-1) and atezolizumab (anti PD-L1) have been approved by the US Food and Drug Administration as first-line single-agent treatments because they significantly prolong overall survival compared with platinum-based chemotherapy, in patients with both squamous and non-squamous tumours without sensitising EGFR mutations or ALK rearrangements.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
